Disease · MONDO_0005264
transient ischemic attack
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. transient ischemic attack. Diseases, record MONDO_0005264. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005264
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Anterior Circulation Transient Ischemic Attack, Attacks, Transient Ischemic, Brain Stem Ischemia, Transient, Brain Stem Transient Ischemic Attack, Brain TIA, Brainstem Ischemia, Transient, Brainstem Ischemias, Transient, Brainstem Transient Ischemic Attack, Carotid Circulation Transient Ischemic Attack, Cerebral Ischemia, Transient, Cerebral Ischemias, Transient, Crescendo Transient Ischemic Attacks, Ischemia, Transient Brainstem, Ischemia, Transient Cerebral, Ischemias, Transient Brainstem, Ischemias, Transient Cerebral, Ischemic Attacks, Transient, Posterior Circulation Transient Ischemic Attack, TIA, TIA (Transient Ischemic Attack), TIA - Transient ischaemic attack, TIA, Brain, TIAs (Transient Ischemic Attack), Transient Brainstem Ischemia, Transient Cerebral Ischemia, Transient Cerebral Ischemias, Transient Ischemic Attack, Anterior Circulation, Transient Ischemic Attack, Brain Stem, Transient Ischemic Attack, Brainstem, Transient Ischemic Attack, Carotid Circulation, Transient Ischemic Attack, Posterior Circulation, Transient Ischemic Attack, Vertebrobasilar Circulation, Transient Ischemic Attacks, Crescendo, Transient cerebral ischaemia, Transient cerebral ischaemia NOS, Transient ischemic attacks (disorder), Vertebrobasilar Circulation Transient Ischemic Attack, attack, transient ischaemic, attack, transient ischemic, ischaemic attack, transient, ischemic attack, transient, transient cerebral ischemia (disorder) [ambiguous], transient ischaemic attack (disease), transient ischaemic attacks, transient ischemic attack (disease), transient ischemic attacks
- Open Targets
Drugs25
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Approval | PMDA | 24 | 20 | 20 | Drugs and targets |
| LANSOPRAZOLE | CHEMBL480 | Small molecule | Approval | PMDA | 2 | 0 | 0 | Drugs and targets |
| VONOPRAZAN FUMARATE | CHEMBL2064032 | Small molecule | Approval | PMDA | 2 | 0 | 0 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 19 | 19 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CILOSTAZOL | CHEMBL799 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DIPYRIDAMOLE | CHEMBL932 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TENECTEPLASE | CHEMBL2108791 | Enzyme | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 25
See all 25 drugsTargets59
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor X | 3 | Coagulation factor X inhibitor | Phase 3 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| P2RY12 | P2Y purinoceptor 12 | 3 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/64805 | Drugs and targets |
| PDE3A | 3',5'-cyclic phosphodiesterase | 3 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/5139 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 2 | Potassium-transporting ATPase inhibitor | Approval | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 2 | Potassium-transporting ATPase inhibitor | Approval | https://conductscience.org/library/genes/496 | Drugs and targets |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | 2 | Subtilisin/kexin type 9 inhibitor | Unknown | https://conductscience.org/library/genes/255738 | Drugs and targets |
| PDE3B | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3 inhibitor | Phase 3 | https://conductscience.org/library/genes/5140 | Drugs and targets |
| ACLY | ATP-citrate synthase | 1 | ATP-citrate synthase inhibitor | Unknown | https://conductscience.org/library/genes/47 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
1 to 10 of 59
See all 59 targetsTrials51
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05321810 | Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation | 193,565 | 2024-01-11 | Non-valvular Atrial Fibrillation | APIXABAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02398656 | A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion | Phase 3 | 1,274 | 2025-01-31 | Stroke, Acute | TENECTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT00816166 | VISSIT Intracranial Stent Study for Ischemic Therapy | Phase 2/3 | 125 | 2014-06-16 | Ischemic Stroke, Transient Ischemic Attack | ASPIRIN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT02415855 | Canadian Pradaxa Acute Stroke Safety Study | 101 | 2020-06-19 | Ischemic Attack, Transient, Stroke | DABIGATRAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01654445 | TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion | Phase 2 | 50 | 2020-11-25 | Ischemic Stroke | TENECTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT04219774 | NeuroCognition After Carotid Recanalization | Phase 2 | 25 | 2025-05-09 | Cognition Disorder, Stroke, Occlusion Carotid | ASPIRIN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT07249164 | Dexmedetomidine Medication Records and Delirium After Coronary Artery Bypass Grafting | 343,112 | Delirium, Cardiac Surgical Procedures, Coronary Artery Bypass Graft (CABG), Valve Surgery, Postoperative Complications | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov | ||
| NCT01924325 | Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events | Phase 2/3 | 10,000 | Ischemic Stroke, TIA | APIXABAN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov | |
| NCT03635749 | Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis | Phase 3 | 6,100 | Acute Stroke, Transient Ischemic Attack | ASPIRIN, ATORVASTATIN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov | |
| NCT01923818 | Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events | Phase 2/3 | 3,700 | Ischemic Stroke, TIA | ASPIRIN, RIVAROXABAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 51
See all 51 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,095 of 7,796 | 1,272 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,061 of 7,796 | 2,393 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,110 of 7,796 | 1,283 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 24 Months: Secondary Prevention (Balanced) Cohorts | 850 of 7,796 | 1,028 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 24 Months: Secondary Prevention (Balanced) Cohorts | 845 of 7,796 | 1,024 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,426 of 7,796 | 1,670 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,448 of 7,796 | 1,685 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,081 of 7,796 | 2,412 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials70
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005264
GET https://conductscience.org/api/diseases/v1/MONDO_0005264/drugs?page=2